April 7th, 2011

posted Apr 5, 2011, 7:47 AM by Victoria Mayer   [ updated Apr 5, 2011, 7:55 AM ]
Bruce R. Bacon, M.D., Stuart C. Gordon, M.D., Eric Lawitz, M.D., Patrick Marcellin, M.D., John M. Vierling, M.D., Stefan Zeuzem, M.D., Fred Poordad, M.D., Zachary D. Goodman, M.D., Ph.D., Heather L. Sings, Ph.D., Navdeep Boparai, M.S., Margaret Burroughs, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Rafael Esteban, M.D., for the HCV RESPOND-2 Investigators. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection.N Engl J Med 2011;364:1207-17.

Fred Poordad, M.D., Jonathan McCone, Jr., M.D., Bruce R. Bacon, M.D., Savino Bruno, M.D., Michael P. Manns, M.D., Mark S. Sulkowski, M.D., Ira M. Jacobson, M.D., K. Rajender Reddy, M.D., Zachary D. Goodman, M.D., Ph.D., Navdeep Boparai, M.S., Mark J. DiNubile, M.D., Vilma Sniukiene, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Jean-Pierre Bronowicki, M.D., Ph.D., for the SPRINT-2 Investigators. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med 2011;364:1195-206. 

Ċ
Victoria Mayer,
Apr 5, 2011, 7:53 AM
Ċ
Victoria Mayer,
Apr 5, 2011, 7:53 AM
Ċ
Victoria Mayer,
Apr 5, 2011, 7:53 AM
Comments